FDA Reviews Roche's Combination Therapy for Lymphoma

The U.S. Food and Drug Administration has accepted Roche's application for a new combination therapy involving Lunsumio and Polivy. This subcutaneous treatment is proposed for adults with relapsed or refractory large B-cell lymphoma, following positive Phase III study results. The data indicated a significant reduction in the risk of disease progression or death.